Distinct leukocyte populations and cytokine secretion profiles define tumoral and peritumoral areas in renal cell carcinoma.

CAFs CD8 T cells Kidney cancer PECAM-1 RCC TME Renal carcinoma immunotherapy Tumor immune microenvironment Tumor-infiltrating lymphocytes cytotoxicity kidney cancer cytokines peritumoral tissue

Journal

Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619

Informations de publication

Date de publication:
03 Feb 2024
Historique:
received: 11 07 2023
revised: 17 11 2023
accepted: 23 01 2024
medline: 5 2 2024
pubmed: 5 2 2024
entrez: 4 2 2024
Statut: aheadofprint

Résumé

Renal cell carcinoma (RCC) is a common malignancy frequently diagnosed at the metastatic stage. We performed a comprehensive analysis of the tumor immune microenvironment (TIME) in RCC patients, including the peritumoral tissue microenvironment, to characterize the phenotypic patterns and functional characteristics of infiltrating immune cells. T cells from various compartments (peripheral blood, tumor, peritumoral area, and adjacent healthy renal tissue) were assessed using flow cytometry and Luminex analyses, both before and after T cell-specific stimulation, to evaluate activation status and migratory potential. Our findings demonstrated that tumor-infiltrating lymphocytes (TILs) exhibited heightened cytokine production compared to peritumoral T cells (pTILs), acting as the primary source of cytotoxic markers (IFN-γ, granzyme B, and FasL). CD8

Identifiants

pubmed: 38310685
pii: S1936-5233(24)00017-2
doi: 10.1016/j.tranon.2024.101891
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101891

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflict of interest. Jirina Bartunkova reports a relationship with Sotio Biotech as that includes: employment.

Auteurs

Martina Borcinova (M)

Gynecologic Oncology Centre, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.

Robin Bartolini (R)

Lausanne Center for Immuno-oncology Toxicities (LCIT), Service of Immunology and Allergy, Department of Medicine, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Lily Koumbas Foley (LK)

Chemokine Research Group, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TT, UK.

Vojtech Novak (V)

Department of Urology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.

Pavla Taborska (P)

Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.

Dmitry Stakheev (D)

Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.

Michal Rataj (M)

Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.

Daniel Smrz (D)

Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.

Martina Fialova (M)

Department of Immunology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Jaromir Hacek (J)

Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University, Prague, Czech Republic.

Martin Komarc (M)

Department of Methodology, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic.

Stepan Vesely (S)

Department of Urology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.

Marek Babjuk (M)

Department of Urology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.

Ilja Striz (I)

Department of Immunology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Jirina Bartunkova (J)

Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.

Tomas Buchler (T)

Department of Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.

Zuzana Ozaniak Strizova (Z)

Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic. Electronic address: zuzana.strizova@fnmotol.cz.

Classifications MeSH